| [1] |
CHEN Weixin.
Analysis of the immune characteristics of peripheral blood lymphocyte subsets in patients with early and advanced non-small cell lung cancer
[J]. Basic & Clinical Medicine, 2026, 46(6): 823-829.
|
| [2] |
YAN Luyu, WANG Chao, FENG Shuo.
FAM83H-AS1 promotes epithelial-mesenchymal transition and angiogenesis in the endometrial cancer cell line Ishikawa
[J]. Basic & Clinical Medicine, 2026, 46(4): 517-523.
|
| [3] |
LIU Pengpeng, SUN Zhao, QIU Wei, TANG Hui, ZHU Wenjia, WANG Wenhui, WANG Yingyi.
Impact of local radiotherapy on tyrosine kinase inhibitor treatment in non-small cell lung cancer with oligo-residual disease
[J]. Basic & Clinical Medicine, 2026, 46(4): 491-497.
|
| [4] |
ZHANG Zhen, YANG Lianren, HU Junkun, ZHANG Wei, LIANG Wei.
Value of serum D-dimer in evaluating chemotherapy effect and prognosis in patients with non-small cell lung cancer
[J]. Basic & Clinical Medicine, 2026, 46(3): 417-420.
|
| [5] |
HUANG Qianqian, JIA Yufang, YU Huajun,CHEN Rongrong,CHEN Lili, WU Jun, ZHANG Haitao.
Stable knockout of ACSS3 in lung cancer cell line using CRISPR/Cas 9 technology
[J]. Basic & Clinical Medicine, 2025, 45(8): 1016-1021.
|
| [6] |
CHEN Lei,REN Weihao,WANG Lide.
Knockdown of translocase of inner mitochondrial membrane 8A enhances gefitinib sensitivity to lung cancer cell line PC-9
[J]. Basic & Clinical Medicine, 2025, 45(8): 1073-1077.
|
| [7] |
YANG Rui, DU Sifen, JIANG Lehui, FU Tian, REN Pengju, JIANG Chengyu, ZHANG Yanli.
Network pharmacology-based screening and validation of tea-derived small molecules against lung cancer
[J]. Basic & Clinical Medicine, 2025, 45(7): 939-946.
|
| [8] |
LOU Haijun, TONG Zhuoyun, ZHANG Zhenyu, Aheyerk·MAHESHATI, MENG·Menggen, WUDU Muli.
Knockdown of DRAM2 inhibits the proliferation and migration of lung cancer cell line A549
[J]. Basic & Clinical Medicine, 2025, 45(2): 197-202.
|
| [9] |
GUO Shuhuan, GAO Yali, CHEN Jingge.
Effect of miR-132-3p on epithelial-mesenchymal transition of trophoblast cells by targeting the SIRT1/NF-κB pathway
[J]. Basic & Clinical Medicine, 2025, 45(12): 1565-1571.
|
| [10] |
CHEN Qingxia, LIANG Yuling, LUO Yalan, NIU Bin.
Inhibition of NRF1/ABCC1 improves chemosensitivity of human lung adenocarcinoma cell lines to cisplatin
[J]. Basic & Clinical Medicine, 2025, 45(1): 51-59.
|
| [11] |
ZHAO Junli, ZHU Junjun, ZHAN Qiunan, LIU Miao.
Bone marrow mesenchymal stem cell-derived exosome inhibits high glucose-induced EMT of peritoneal mesothelial cells
[J]. Basic & Clinical Medicine, 2024, 44(8): 1149-1156.
|
| [12] |
ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan.
Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549
[J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
|
| [13] |
CAO Chenxin, TANG Hui, GENG Ruixuan, GUO Fuping, BAI Chunmei, WANG Yingyi, LI Taisheng.
Correlation between circulating CD4+CD45RA+CD62L+ T cells and prognosis of metastatic non-small cell lung cancer treated with EGFR-TKI
[J]. Basic & Clinical Medicine, 2024, 44(5): 658-664.
|
| [14] |
LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang.
Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis
[J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
|
| [15] |
ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin.
Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib
[J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
|